Homepage | Journal of Neurology, Neurosurgery and Psychiatry …
3 days ago · Journal of Neurology, Neurosurgery and Psychiatry (JNNP)'s ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson's disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen ...
Authors | Journal of Neurology, Neurosurgery and Psychiatry …
The Journal of Neurology, Neurosurgery, and Psychiatry (JNNP) publishes original articles, short reports, editorials, commentaries and more, covering the whole field of clinical neurological practice, neurosurgery and neuropsychiatry.Emphasis is given to common disorders such as cerebrovascular disease, multiple sclerosis, Parkinson’s …
Pathophysiology, diagnosis and care of Alzheimer’s disease are …
Nov 12, 2024 · Introduction. Until recently, pathophysiological models, diagnosis and care of Alzheimer’s disease have been strikingly uncoupled. The dominant pathophysiological theory was the canonical amyloid hypothesis (cAH), a deterministic framework postulating that the extraneuronal deposition of amyloid β aggregates is the earliest and causative event that triggers a cascade of downstream events ...
About - Journal of Neurology, Neurosurgery and Psychiatry (JNNP)
Journal of Neurology, Neurosurgery & Psychiatry (JNNP)’s ambition is to publish the most ground-breaking and cutting-edge research from around the world. Encompassing the entire genre of neurological sciences, our focus is on the common disorders (stroke, multiple sclerosis, Parkinson’s disease, epilepsy, peripheral neuropathy, subarachnoid haemorrhage and neuropsychiatry), but with a keen ...
Incidence and prevalence of functional neurological disorder: a ...
Dec 11, 2024 · Background Robust epidemiological data regarding population incidence and prevalence of functional neurological disorder (FND) would be helpful with regards to resource allocation and planning for this disorder, particularly given high symptom burden and high healthcare utilisation. We therefore aimed to systematically review and synthesise available data on FND incidence and prevalence ...
Browse by topic - Journal of Neurology, Neurosurgery and …
Email alerts. Browse by collection. 2020 Hindsight; 2020 Vision; COVID-19; Editor's choice; JNNP Impact commentaries
C5 complement inhibition and FcRn modulation in generalized …
2 days ago · The paper by Huntemann et al 1 exploits almost identical indications for the treatment of generalised myasthenia gravis (MG) with efgartigimod (a neonatal Fcγ receptor blocker (FcRn blocker)) and ravulizumab (a C5 complement inhibitor) to conduct an elegant real-world study comparing their efficacy and safety as add-on therapies to conventional care. Their data showed positive treatment ...
Fewer relapses and worse outcomes of patients with late-onset …
Dec 6, 2024 · Background To delineate the clinical characteristics and outcomes of late-onset myelin oligodendrocyte glycoprotein antibody-associated disease (LO-MOGAD) and compare them with those of early-onset MOGAD (EO-MOGAD). Methods This observational cohort study included 199 adult patients with MOGAD. We reviewed the patients’ demographic and clinical data and performed comparative analyses between ...
Most Read Articles | Journal of Neurology, Neurosurgery and Psychiatry ...
Feb 14, 2024 · Edoardo Caronna, Victor José Gallardo, Gabriella Egeo, Manuel Millán Vázquez, Candela Nieves Castellanos, Javier A Membrilla, Gloria Vaghi, Joana Rodríguez-Montolio, Neus Fabregat Fabra, Francisco Sánchez-Caballero, Alex Jaimes Sánchez, Albert Muñoz-Vendrell, Renato Oliveira, Gabriel Gárate, Yésica González-Osorio See the full list of authors
C5 complement inhibition versus FcRn modulation in generalised ...
2 days ago · Background Myasthenia gravis (MG) is an autoimmune disorder affecting neuromuscular junctions, leading to fluctuating muscle weakness. While many patients respond well to standard immunosuppression, a substantial subgroup faces ongoing disease activity. Emerging treatments such as complement factor C5 inhibition (C5IT) and neonatal Fc receptor (FcRn) antagonism hold promise for these patients ...